Skip to content

This Site is Intended for Healthcare Professionals Only

Search AI Powered

Latest Stories

RPS appoints Parastou Donyai as chief scientist

The Royal Pharmaceutical Society (RPS) has appointed Professor Parastou Donyai as chief scientist. She will take up the role in June.

Parastou is a pharmacist with a PhD in pharmacy. She also has a postgraduate diploma in Psychological Research Methods as well as a degree in Psychology.


She is currently a professor of Social & Cognitive Pharmacy at the University of Reading and her research examines the psychology of medication use, discontinuation and decision-making processes.

Prior to this, Parastou also spent more than five years as a senior lecturer in Pharmacy Practice at Kingston University and St. George's University of London. Her longstanding research interest includes continuing professional development in pharmacy.

Commenting on her appointment, Parastou said: "It is a real privilege for me to be the Royal Pharmaceutical Society’s next chief scientist.

"As a pharmacist, scientist and academic, I look forward to working with the Royal Pharmaceutical Society’s members and key stakeholders to uphold the value of science across the breadth of our profession."

Paul Bennett, RPS CEO, said: “I am delighted to welcome Parastou to the RPS team. As a pharmacist and member of the RPS, she has a wealth of experience across pharmaceutical sciences and different sectors of the profession and is in a great position to take forward our work on science as the underpinning discipline to pharmacy practice.

"With her academic strength, having undergraduate degrees in pharmacy and psychology, as well as her laboratory based doctorate and as a Fellow of the Higher Education Academy, she brings a unique and valuable set of skills to RPS.”

More For You

Chemotherapy-free leukaemia treatment

The trial found that a combination of two cancer drugs, ibrutinib and venetoclax, could perform better than chemotherapy among patients with chronic lymphocytic leukaemia.

iStock

Chemotherapy-free leukaemia treatment shows promise during trial

In a breakthrough in leukaemia research, scientists in the UK have tested a chemotherapy-free approach, involving a combination of targeted drugs, which may offer better outcomes.

The new treatment could radically change the way chronic lymphocytic leukaemia (CLL), the most common form of leukaemia in adults, is treated.

Keep ReadingShow less
Wales ranked worst for second-trimester abortion access in the UK

Each year about 175 women travel from Wales to England for care

Wales ranked worst for second-trimester abortion access in the UK

A leading healthcare charity has revealed that Wales is the worst part of the United Kingdom for allowing surgical abortions for women.

Surgical abortion is the process removing pregnancy from the womb by inducing local anaesthesia, conscious sedation or general anaesthesia.

Keep ReadingShow less
The fund offers £150 per eligible child - for up to three children per household.

The fund offers £150 per eligible child - for up to three children per household.

Charity reopens funding to ease back to school financial pressures for community pharmacists

Community pharmacists struggling with the costs of their children going back to school can apply for funding from The Leverhulme Trade Charities Trust (LTCT)

The Trust is providing up to £100,000 of support to those working in a community pharmacy or are a registered pharmacist or pharmacy technician

Keep ReadingShow less
Germany's BioNTech to buy CureVac to boost cancer research

Both biotech companies have been working for years in the area of mRNA vaccines and treatments

Germany's BioNTech to buy CureVac to boost cancer research

Germany's BioNTech is buying domestic rival CureVac for $1.25 billion, bringing together two pharmaceutical firms specialised in mRNA technology with the goal of advancing cancer treatments.

BioNTech, which developed the first coronavirus vaccine to be approved in the West along with US pharmaceutical giant Pfizer, said the acquisition would "bring together complementary capabilities and leverage technologies".

Keep ReadingShow less
Amandeep Doll RPS  New Director of England

Amandeep Doll

RPS announces new director of England

Amandeep Doll has been named as the new director for England at the Royal Pharmaceutical Society (RPS).

The role of Director for England drives professional leadership for the pharmacy profession in England, and leads on national policy development and advocacy across England, in partnership with the English Pharmacy Board.

Keep ReadingShow less